Proglycem Side Effects May Increase Risk of Pulmonary Hypertension In Newborns: FDA Warns

Irvin Jackson

Add Your Comments

Federal drug regulators are warning that side effects of Proglycem, a drug used to treat low blood sugar, may increase the risk of a dangerous respiratory problems when given to infants and newborns. 

The FDA issued a drug safety communication on July 16, indicating that Proglycem (diazoxide) may cause pulmonary hypertension in infants and newborns, who sometimes receive the drug when hospitalized.

The agency indicates that it is investigating the issue and trying to determine whether any regulatory actions are needed, or whether the label warnings for the drug need to be changed.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

According to the FDA there have been only 11 cases of pulmonary hypertension in newborns or infants given Proglycem since its approval in 1973. However, the agency found that in every case the infant’s condition improved or resolved completely after Proglycem treatments were stopped.

The agency is warning health care professionals to closely monitor babies given the drug, especially those children with respiratory problems that could increase their risks of pulmonary hypertension. These problems could inculde meconium aspiration syndrome, respiratory distress syndrome, transient tachypnea, pneumonia, sepsis, congenital diaphramic hernia or congenital heart disease. The FDA warns doctors to stop Proglycem treatment immediately if the baby is diagnosed with pulmonary hypertension.

Parents and caregivers are being warned to watch children given the medication for signs of difficulty breathing, including:

  • Flaring nostrils
  • Grunting
  • Unusual chest movements
  • Rapid breathing
  • Difficulty eating
  • Bluish skin or lips

They should notify a healthcare professional immediately if any of these signs are observed.

Proglycem, a liquid taken by mouth, is used to treat low blood sugar by blocking the pancreas from creating insulin. The Merck drug has been on the market since 1973.

The FDA discovered the cases of pulmonary hypertension by searching medical literature and its own adverse event reporting database.

Irvin Jackson
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Tags: Children, Proglycem, Pulmonary Hypertension

More Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Juror Selection Underway in First Bard PowerPort Trial Over Infection Claims
The first Bard PowerPort lawsuit bellwether trial commences next week involving claims that a man suffered a severe infection due to the port catheter’s allegedly defective design.
Hearings on Evidence That Depo-Provera Causes Meningioma Brain Tumors Set for Late June 2026
A federal judge has scheduled general causation hearings for Depo-Provera brain tumor lawsuits for June 24 through 26.
WaveWriter Alpha Lawsuit Claims Defective Spinal Cord Stimulator Caused Pain and Surgical Removal
A Louisiana man’s Boston Scientific WaveWriter Alpha SCS lawsuit claims the implant failed to provide the promised pain relief and, in fact, made things worse before it needed to be surgically removed.